0.4727
price up icon0.79%   0.0037
after-market After Hours: .48 0.0073 +1.54%
loading
Equillium Inc stock is traded at $0.4727, with a volume of 171.28K. It is up +0.79% in the last 24 hours and down -33.42% over the past month. Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.469
Open:
$0.4602
24h Volume:
171.28K
Relative Volume:
0.22
Market Cap:
$16.83M
Revenue:
$45.91M
Net Income/Loss:
$-4.62M
P/E Ratio:
-3.3716
EPS:
-0.1402
Net Cash Flow:
$-21.51M
1W Performance:
+16.60%
1M Performance:
-33.42%
6M Performance:
-45.34%
1Y Performance:
-78.71%
1-Day Range:
Value
$0.4312
$0.5298
1-Week Range:
Value
$0.3642
$0.55
52-Week Range:
Value
$0.3642
$2.26

Equillium Inc Stock (EQ) Company Profile

Name
Name
Equillium Inc
Name
Phone
(858) 412-5302
Name
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Name
Employee
45
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
EQ's Discussions on Twitter

Compare EQ with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
EQ
Equillium Inc
0.4727 16.83M 45.91M -4.62M -21.51M -0.1402
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Equillium Inc Stock (EQ) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-28-25 Downgrade Leerink Partners Outperform → Market Perform
Oct-29-21 Resumed Stifel Buy
Sep-15-21 Initiated Cantor Fitzgerald Overweight
Jul-14-20 Reiterated H.C. Wainwright Buy
Jul-10-20 Resumed Stifel Buy
Feb-22-19 Initiated SVB Leerink Outperform
View All

Equillium Inc Stock (EQ) Latest News

pulisher
Apr 01, 2025

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium stock tumbles on Phase 3 study results - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

Equillium Reports 2024 Financials and Clinical Milestones - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe

Mar 27, 2025
pulisher
Mar 17, 2025

Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World

Mar 17, 2025
pulisher
Mar 07, 2025

Equillium Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Feb 28, 2025

SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Equillium stock rallies 26% on itolizumab study data - MSN

Feb 28, 2025
pulisher
Feb 21, 2025

Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research

Feb 21, 2025
pulisher
Feb 12, 2025

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St

Feb 12, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq

Feb 10, 2025
pulisher
Feb 10, 2025

Healthy Upside Potential: Equillium Inc (EQ) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle

Feb 10, 2025
pulisher
Feb 10, 2025

Equillium reports positive Phase 2 ulcerative colitis study data - MSN

Feb 10, 2025
pulisher
Feb 07, 2025

why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News

Feb 07, 2025
pulisher
Feb 07, 2025

Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily

Feb 07, 2025
pulisher
Feb 07, 2025

CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com

Feb 07, 2025
pulisher
Feb 07, 2025

Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis - Indian Pharma Post

Feb 07, 2025
pulisher
Feb 07, 2025

UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK

Feb 07, 2025
pulisher
Feb 07, 2025

Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues

Feb 07, 2025
pulisher
Feb 06, 2025

Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa

Feb 06, 2025

Equillium Inc Stock (EQ) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):